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Abstract
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A series of five boron dipyrromethene (BODIPY) bioconjugates containing an epidermal growth
factor receptor (EGFR)-targeted pegylated LARLLT peptide and/or a glucose or biotin ethylene
diamine group were synthesized, and the binding capability of the new conjugates to the
extracellular domain of EGFR was investigated using molecular modeling, surface plasmon
resonance, fluorescence microscopy, competitive binding assays, and animal studies. The
BODIPY conjugates with a LARLLT peptide were found to bind specifically to EGFR, whereas
those lacking the peptide bound weakly and nonspecifically. All BODIPY conjugates showed low
cytotoxicity (IC50 > 94 μM) in HT-29 cells, both in the dark and upon light activation (1.5 J/cm2).
Studies of nude mice bearing subcutaneous human HT-29 xenografts revealed that only BODIPY
conjugates bearing the LARLLT peptide showed tumor localization 24 h after intravenous
administration. The results of our studies demonstrate that BODIPY bioconjugates bearing the
EGFR-targeting peptide 3PEG-LARLLT show promise as near-IR fluorescent imaging agents for
colon cancers overexpressing EGFR.
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1.

INTRODUCTION

Author Manuscript

Molecular imaging, specifically near infrared (NIR) imaging, is revolutionizing the field of
colon cancer research as it allows for the noninvasive in vivo detection of raised polyps and
flat colorectal neoplasms.1,2 Several techniques currently exist for the detection and
treatment of colorectal cancer (CRC), including computed tomography colonography, fecal
occult blood tests, and sigmoidoscopy, each experiencing limitations and/or disadvantages.
3,4 Adenomas diagnosed at an early stage are typically removed surgically; however, over
20% of colon cancers are already at stage IV at the time of diagnosis.5 Therefore, there is
still a need for alternative or complementary methods of early detection of tumors where
careful selection of tumor biomarkers that are amply available on the surface of cancer cells
is crucial to the detection and subsequent treatment of CRC.5,6,8

Author Manuscript

Epidermal growth factor receptor (EGFR) is a ~ 180 kDa (1210 AA) transmembrane
glycoprotein that contains an extracellular domain (ECD), single transmembrane domain,
and intracellular tyrosine kinase domain.23–25 Within the ECD lies a ligand-binding cleft
that can interact with a number of various ligands, including EGF and TGF-α.22 Ligand
binding induces EGFR homo- and/or hetero-dimerization, as well as tyrosine
autophosphorylation, and leads to cell proliferation and the initiation of intracellular
signaling pathways.22 In vitro studies have shown that metastatic cells may express 5 to 100
times more EGFR compared with nonmetastatic cells.7 Tumor cells overexpressing
membrane-bound EGFR can be targeted for therapy by combining NIR fluorescent
molecules with biological labels. This can be achieved through the facile coupling of
biological probes that have intrinsic specificity (binding properties) for the EGFR biomarker
(i.e., aptamers, antibodies, or peptides), with highly fluorescent and nontoxic molecules such
as boron dipyrromethenes.6
4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene (abbreviated BODIPY or boron
dipyrromethene) dyes are versatile small molecules with many desirable characteristics
including strong UV-absorption and sharp fluorescence emission peaks, large molar
absorption coefficients (ε = 50 000–100 000 M−1 cm−1), relatively long excited singlet-state
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lifetimes (> 5 ns), negligible excited triplet state formation, and high fluorescence quantum
yields (Ф > 0.5).13,17,26 In addition to their excellent photophysical properties, they are
relatively stable under physiological conditions and fairly insensitive to changes in polarity
and pH of their environment.13 BODIPY dyes are becoming increasingly useful in the
rapidly expanding field of NIR and far-red imaging. Optical and NIR wavelengths typically
span from 400 up to 2500 nm, however several tissue components absorb light within this
range, making in vivo imaging through tissue difficult. The wavelength range of 650–1450
nm falls in the region of the spectrum with the lowest tissue absorption and with careful
design BODIPY can be tuned to both absorb light and emit fluorescence within this longwavelength “imaging window” of minimal tissue absorbance and minimal autofluorescence.
27

Author Manuscript

In 2005 Li et al.28 reported peptide GE11 (YHWY-GYTPQNVI or EGFR-L2), which was
identified through screening of a phage display peptide library. Then, in 2009, Song et al.31
reported peptide D4 (LARLLT or EGFR-L1) which was discovered using a computer-aided
design approach (structure-based peptide design). Both GE11 and D4 peptides show high
affinity for the epidermal growth factor receptor (EGFR) both in vitro and in vivo. Our
group has previously reported porphyrin,29 phthalocyanine,30 and BODIPY9 fluorophores
designed to target EGFR utilizing EGFR-L1, EGFR-L2, and tri-(ethylene)glycol-LARLLT
(3PEG-EGFR-L1) with the latter peptide showing the most promise in previous studies
because of its improved water solubility and binding resulting in higher intracellular
accumulation.9,29,30 Additionally, enhanced binding was observed in surface plasmon
resonance (SPR) studies when two 3PEG-EGFR-L1 peptides were conjugated to a single
porphyrin molecule compared with a single 3PEG-EGFR-L1 peptide.29 This observed
binding enhancement may be due to the amphiphilic character of the conjugates with the
additional peptide positive charge and/or the potential for binding two, rather than one,
EGFR molecules simultaneously.29 On the basis of this previous work, we envisioned the
conjugation of two EGFR targeting 3PEG-EGFR-L1 peptides to a single BODIPY molecule
that was tuned to excite and emit in the far-red/near-IR region for the purpose of NIR
imaging. On the other hand, the role of saccharides in cell recognition and labeling is well
known with several researchers having previously reported the conjugation of multiple
carbohydrate units (galactose or lactose) to porphyrin platforms.16–20 Our group has also
reported the conjugation of carbohydrates to BODIPYs, which resulted in increased cellular
uptake and permeability.17 Herein, we report the conjugation of a BODIPY bearing two
isocyanato functionalities to the 3PEG-EGFR-L1 peptide, and/or glucose or biotin units. The
resulting five conjugates were evaluated in vitro using various cell lines with different EGFR
expressions. The most promising BODIPY conjugate bearing one 3PEG-EGFR-L1 and one
glucose unit was further evaluated in nude mice bearing subcutaneous human HT-29
xenografts.
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2.
2.1.

RESULTS AND DISCUSSION
Synthesis and Characterization.
Our group has recently reported the synthesis of a dichlorinated BODIPY bearing a single
isothiocyanate functional group, which was used to conjugate EGFR-targeting pegylated
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peptides 3PEG-LARLLT and 3PEG-GYHWYGYTPQNVI, in yields of 80 and 50%,
respectively.9 Among these, the BODIPY conjugate bearing the LARLLT peptide was found
to have enhanced EGFR-binding ability. On the basis of this work, we decided to synthesize
a further red-shifted BODIPY bearing two isothiocyanate functional groups for conjugation
to two peptides rather than one or to one peptide and another biomolecule. By inducing a
bathochromic shift in both the excitation and emission wavelengths of the BODIPY through
functionalization at the 3,5-positions with aryl groups, as well as benzo-fusion to the β,β′pyrrolic positions, we anticipated to lower tissue absorption and increase tissue penetration.
The novel incorporation of a second isothiocyanate group to the BODIPY framework affords
a second conjugation site for an additional peptide or biomolecule to further enhance tumor
selectivity, solubility, and cell permeability.

Author Manuscript

The precursor BODIPY 10 bearing two p-isothiocyanatophenyl groups at the 3- and 5positions was prepared in nine steps as shown in Scheme 1. The synthetic route to BODIPY
10 began with a Barton–Zard10 reaction between 1-nitro-cyclohexene and ethyl
isocyanoacetate to form the ester functionalized tetrahydro-2H-isoindole 2 in 80% yield,
using 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU) as a base. This was followed by a Lindsey
condensation11 to form dipyrromethane 3 in 84% yield, using p-TsOH as the catalyst.37,38
Ester cleavage under basic conditions gave dipyrromethane 4, which underwent
decarboxylative iodination under dark conditions to avoid photolytic cleavage of I2, in the
presence of NaHCO3 (aq) to yield dipyrromethene 5. Through a boron complexation
reaction, BODIPY 6 was then prepared in 68% yield, by treating dipyrromethene 5 with
BF3·OEt2 in the presence of TEA.13

Author Manuscript

With BODIPY 6 in hand, Suzuki–Miyaura coupling was carried out using 5 equiv of 4nitrophenylboronic acid in the presence of 1 M K2CO3 (aq) using Pd(dppf)Cl2 as the
catalyst,12 which gave BODIPY 7 in 73 –99% isolated yield. Full aromatization of the
BODIPY core was achieved with the use of 9 equiv 2,3-dichloro-5,6-dicyano-1,4benzoquinone (DDQ) in refluxing toluene, monitored by UV/vis, to yield BODIPY 8 in 54–
93% yield.13 Reduction of the aryl nitro groups was carried out with 10 wt % palladium on
carbon and hydrazine in a mixture of ethanol and tetrahydrofuran (THF). Finally, conversion
of the aryl amines to aryl isothiocyanato groups was accomplished using 1, 1′thiocarbonyldi-2(1H)-pyridone (TDP) in CH2Cl2 to yield BODIPY 10 in 90% yield.9 The
structures of the new BODIPYs were confirmed by 1H-,13C-, and 11B-NMR and by HRMS
[electrospray ionization-time of flight (ESI-TOF)] methodologies (see the Supporting
Information).

Author Manuscript

An adequate single crystal of zaffre blue BODIPY 10 was obtained through slow
evaporation of chloroform. X-ray crystallographic analysis unambiguously elucidated a
structure in which the BF2 moiety is disordered into two conformations with approximately
2:1 populations, the F atoms tilted slightly in either direction from symmetric disposition
about the central plane. Only one of these is depicted in Figure 1. Interestingly, it was
necessary to determine the structure at 180 K because a phase change destroyed the crystal
at lower temperatures. The color of the material also changed from blue to emerald green
when cooled below the transition temperature. The B–N distances for BODIPY 10 average
1.554(2) Å, which denotes the characteristic delocalization of the positive charge.32 The
J Med Chem. Author manuscript; available in PMC 2019 August 14.
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central C3N2B core of the BODIPY is nearly planar, with mean out-of-plane deviation 0.011
Å. This plane forms dihedral angles of 57.6 and 62.1° with the 3,5-aryl planes and dihedral
angle of 78.4° with the meso-aryl plane.

Author Manuscript

On the basis of our previous studies, peptide 3PEG-LARLLT was selected for conjugation
with BODIPY 10. This peptide was synthesized on Fmoc-Pal-PEG-PS resin using solidphase peptide synthesis (SPPS), as previously reported.9,26,29,30,33 In brief, O-benzotriazoleN,N,N′,N′-tetramethyl-uronium-hexafluorophosphate (HBTU), 1-hydroxybenzotriazole
(HOBt), and diisopropylethylamine (DIPEA) were utilized as the coupling reagents and a
20% piperidine solution was employed for Fmoc group deprotection. The deprotected
peptide was cleaved from the resin using a cocktail solution of trifluoroacetic acid (TFA;
94%), MQ water (2.5%), liquefied phenol (2.5%), and triisopropylsilane (TIPS; 1%), and the
cleaved peptide was purified using reversed-phase high-performance liquid chromatography
(RP-HPLC). Nucle-ophilic addition of the purified peptide 3PEG-LARLLT (>95% purity, 2
equiv) was carried out with BODIPY 10 in anhydrous dimethylformamide (DMF) in the
presence of TEA, for 30 min at room temperature,9 affording BODIPY conjugate 11 in 90%
yield (Scheme 2). Only one of the isothiocyanato groups of BODIPY 10 reacted with
formation of a single thiourea bond. Several attempts were explored to elicit peptide
diconjugation, including using a larger excess of peptide and varying the reaction time and
concentration of reagents, but no di-peptide substituted BODIPY was observed. Therefore,
purified mono-conjugate 11 was treated with 3PEG-LARLLT peptide in anhydrous DMF
and TEA, but still no di-peptide BODIPY conjugate was obtained. This result could be due
to the initial conjugated peptide adopting a conformation in situ that wraps around the
BODIPY, blocking the second isothiocyanate conjugation site.

Author Manuscript

In an effort to enhance the solubility and receptor binding, the second isothiocyanato
functional group was further functionalized with either 1-thio-β-D-glucose sodium salt or
ethylene diamine-modified biotin (biotin-en), as previously studies reported enhanced
cellular permeability and pharmacokinetic properties when these biomolecules were
incorporated into the parent molecule.17,34,35 Therefore, conjugate 11 and 5 equiv of 1-thioβ-D-glucose sodium salt or biotin-en were independently solubilized in dimethylsulfoxide
(DMSO) and then combined and reacted in the presence of TEA for 30 min at room
temperature, yielding conjugates 12 and 13 in 83 and 45% yields, respectively. BODIPY 10
was also reacted with 2.5 equiv of 1-thio-β-D-glucose sodium salt or biotin-en, to give the
corresponding di-conjugated products, 14 and 15 in 43 and 11% yields, respectively. The
bioconjugates 12, 13, 14, and 15 were purified using RP-H PLC, and their structures were
characterized using 1HNMR, heteronuclear single quantum correlation (HSQC), and matrix
assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) (see the
Supporting Information).
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2.2.

Spectroscopic Investigations.
The spectroscopic properties of BODIPY bioconjugates 11–15 in DMSO, including their
maximum absorption and emission wavelengths, Stokes’ shifts, fluorescence quantum
yields, and molar extinction coefficients, were investigated, and the results are summarized
in Table 1. Figures S22 and S23 of the Supporting Information show the normalized
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absorption and emission spectra for the bioconjugates. All compounds showed π → π*
absorption bands between 650 and 657 nm and emission wavelengths in the NIR range
between 689 and 696 nm in DMSO. The Stokes’ shifts for all compounds were between 38
and 40 nm, and the molar extinction coefficients (ε) ranged from 13 700 to 72 600 M−1 cm
−1, as is characteristic for BODIPY–peptide conjugates. All compounds showed
fluorescence quantum yields (ФF) in the range of 0.37–0.47 in DMSO.
All BODIPY bioconjugates were soluble in polar organic solvents, such as DMSO. Their
polar surface area (PSA) values, which measure their solvent-accessible surface area, were
calculated and the results are also shown in Table 1. The peptide-containing conjugates
showed similar PSA values, indicating that they have similar cellular permeability.
2.3.

SPR Studies.

Author Manuscript

SPR was used to determine the binding affinities of compounds 10 and 11–14 with EGFR
protein ECD because it allows real-time, label-free detection of biomolecular interactions.
14,15 Sensorgrams of binding of BODIPYs 12 and 13 are shown in Figure 2 (the
sensorgrams for BODIPYs 10,11, and 14 are shown in Figure S25B,C,A of the Supporting
Information). BODIPYs 12 and 13 both exhibited a stepwise binding to EGFR ECD with
kinetics of association of 200 s and dissociation for the next 300 s. The sensorgrams
indicated a slow increase in response with saturation behavior suggesting that binding of
these BODIPYs is specific to EGFR ECD. Similar results were observed for BODIPY 11
(Figure S25C of the Supporting Information). In the case of BODIPY 14 (Figure S25A,
Supporting Information), binding or association was rapid, as there was a very steep increase
in the association phase and slow dissociation phase. Furthermore, at high concentration
(250 μM), there was a decrease in response compared with that at 100 μM. For the bis-NCS
BODIPY 10 (Figure S25B, Supporting Information), the sensorgrams were not stepwise
upon addition of different concentrations of compound, suggesting nonspecific binding or
weak binding of this BODIPY. The dissociation constants (KD) were also calculated using a
1:1 binding fit with KD values of 2.635 × 10−3 and 3.083 × 10−6 M for 12 and 13,
respectively (Table S1 in Supporting Information). Overall, the SPR studies clearly indicated
that the BODIPYs conjugated with peptide 3PEG-LARLLT exhibited specific binding to
EGFR ECD while the BODIPYs lacking peptide, 10 and 14, bound to EGFR
nonspecifically.

Author Manuscript
2.4.

Modeling and Docking.
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To model the interaction of BODIPYs 11–15 with EGFR, three-dimensional structures of
these conjugates, as well as of BODIPY 10, were generated, and the 3D structures of the
conjugates were docked to the EGFR closed conformation using AutoDock.39 The results of
these studies are shown in Figure 3 for BODIPYs 12 and 14 (and Figure S26C, D, A, B of
the Supporting Information for BODIPYs 10, 11, 13, and 15). Peptide LARLLT is known to
bind to domain I of EGFR, away from the EGF binding pocket,31 and thus, BODIPYs 10–15
were docked on domain I of EGFR. Conjugate 13 was found to bind near the LARLLT
peptide binding pocket, with three possible hydrogen bonds and hydrophobic interactions.
Residue T6 of the peptide formed hydrogen bonds with Glu78 and Asn79. The aromatic
groups of BODIPY were involved in hydrophobic interactions with Leu225, Lys185,
J Med Chem. Author manuscript; available in PMC 2019 August 14.
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Pro171, Ile189 and 190, and Lys202 side chains. The biotin-en groups formed a hydrogen
bond interaction with Arg200. Furthermore, the PEG linker of the peptide, R3 side chain,
and backbone amides of L6 formed polar interactions with Gln78, Asn79, Glu35, Gln59,
and Gln81 of EGFR. Overall, the peptide structure was stabilized on domain I of EGFR
binding pocket with a docking energy of −4.21 kcal/mol. BODIPY conjugates 11 (Figure
S26D) and 12 (Figure 3), also containing one LARLLT peptide, formed similar interactions
with domain I of EGFR as described above for 13. In the case of BODIPY 12 (Figure 3), the
glucose moiety formed additional hydrogen bond interactions with Arg200 of EGFR.
Docking energies for BODIPYs 11 and 12 were −4.73 and −4.00 kcal/mol, respectively,
which are within the calculation error of up to 2 kcal/mol. On the other hand, BODIPYs 14
(Figure 3), 15 (Figure S26B), and 10 (Figure S26C), bearing no peptide, appear to bind
nonspecifically to EGFR. Docking studies indicated that there are two possible binding sites
for these BODIPYs, with the lowest energy docked structures located in a buried
hydrophobic pocket away from the binding site defined for the LARLLT peptide. The
second possible binding site was near Pro171, Ile189, 190, and Lys202. For BODIPY 10, all
of the possible binding sites were away from the LARLLT binding pocket on EGFR. The
lowest docking energies for BODIPYs 14, 15, and 10 were found to be −8.4, −8.9, and
−11.1 kcal/mol, respectively. The docking energy depends on how deeply buried a molecule
is, as well as the number of rotatable bonds in the molecule. Because the BODIPYs without
peptide were mostly hydrophobic with rigid aromatic structures, the docking energy was
lower than that for the BODIPYs containing the LARLLT peptide. These results are
consistent with the SPR data which suggest that the peptide-containing BODIPYs 11, 12,
and 13 bind to domain I of EGFR, while BODIPYs 10, 14, and 15 containing no peptide
bind nonspecifically in deep hydrophobic binding pockets on EGFR.

Author Manuscript
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2.5.

In Vitro Studies.
Several cell lines with different expressions of EGFR were used to investigate the cell
membrane localization, uptake, and cytotoxicity of BODIPY conjugates 12, 13, 14, and 15.
The human colorectal adenocarcinoma cell line HT-29 is considered a pluripotent intestinal
cell line and is widely used to study the biology of human cancers.5 Human colon cancer
cell lines SW480 (129% EGFR expression), HT-29 (78% EGFR expression), DLD-1 (37%
EGFR expression), and LOVO (6% EGFR expression) were purchased from the American
Type Culture Collection (ATCC) (Manassas, Virginia, USA) and chosen to ensure that a full
spectrum of cell surface EGFR expression was examined.8

Author Manuscript

2.5.1. Competitive Binding Studies.—The specificity of BODIPY binding to EGFR
on colon cancer cells was investigated by competitive binding of conjugates 12 and 14 with
unlabeled cyclo(K(N3)larllt) peptide,21 which has been shown to bind to EGFR with high
affinity. The results obtained are shown in Figures 4 and S27 (the Supporting Information).
The colon cancer cell lines SW480 (high EGFR expression), HT-29 and DLD-1 (moderate
EGFR expression), and LOVO (low EGFR expression) were used in these studies.8 When
BODIPY 12 (50 μM) was incubated with unlabeled cyclic peptide at concentrations up to
100 μM, a dose-dependent decrease in fluorescence was observed in the cell lines with high
and moderate EGFR expression but not in LOVO cells(Figure 4). The highest inhibition of
fluorescence intensity was observed in the SW480 cell line with the highest expression of
J Med Chem. Author manuscript; available in PMC 2019 August 14.
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EGFR, followed by HT-29 and DLD-1 cells, indicating the replacement of unlabeled peptide
specifically in the high EGFR expressing cells. On the other hand, the incubation of
unlabeled peptide with BODIPY 12 in LOVO cells, with low EGFR expression, did not
result in a concentration-dependent response of the fluorescence intensity. A decrease in
fluorescence was nevertheless observed upon addition of unlabeled cyclic peptide,
suggesting some nonspecific binding of the conjugate to the LOVO cells. Similar studies
were carried out with BODIPY 14, which contains two glucose units and bears no EGFRtargeting LARLLT peptide. In this case, competitive binding of 14 in the presence of
unlabeled cyclic peptide, led to no concentration-dependent response of the fluorescence
intensity in all four cell lines, although a decrease in fluorescence was observed upon
addition of unlabeled cyclic peptide. This result suggests some nonspecific binding of
conjugate 14 (Figure S27, the Supporting Information). These results are in agreement with
the SPR studies and indicate that BODIPYs bearing the LARLLT peptide bind to EGFR
specifically, whereas BODIPYs without peptide bind to EGFR nonspecifically.
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2.5.2. Time-Dependent Cellular Uptake.—The uptake BODIPYs 12, 13, 14, and 15
by human colorectal adenocarcinoma HT-29 cells was investigated at a concentration of 10
μM over a 24 h period. Figure 5 shows the results obtained in these studies. BODIPYs 12
and 13 bearing the LARLLT peptide showed similar uptake kinetics with rapid accumulation
in the first 8 h, after which a plateau was reached. BODIPY 12 accumulated the most within
cells of all BODIPYs up to 12 h, but at 24 h, the bis-biotin conjugate 15 showed the highest
uptake of all. This is due to the continuous increasing in the uptake of 15 over the 24 h
period investigated. At all time points investigated, BODIPY 12 showed higher uptake than
13 because of the presence of glucose in 12 in place of the biotin group in 13, suggesting
that glucose enhances the cellular uptake. However, BODIPY 14 bearing two glucose units
accumulated the least within cells of all BODIPYs. These results indicate that because the
glucose groups modulate the hydrophobic character of the conjugates, one glucose leads to
an amphiphilic molecule with enhanced cellular uptake, whereas two glucoses lead to a
more hydrophilic conjugate with decreased uptake. On the other hand conjugate 15
containing two biotin groups showed continued uptake over the 24 h period, suggesting a
different cellular uptake mechanism from BODIPYs 12 and 13 bearing the EGFR-targeting
peptide.
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2.5.3. Cytotoxicity.—The cytotoxicity of BODIPYs 12, 13, 14, and 15 was evaluated in
human colorectal adenocarcinoma HT-29 cells using a CellTiter Blue (CTB) assay. The
results of these studies are shown in Table 2 (and Figures S28 and S29 of the Supporting
Information). The BODIPY conjugates were analyzed at up to 200 μM concentrations for
dark toxicity and at up to 100 μM concentrations for phototoxicity using a low light dose of
approximately 1.5 J/cm2. In the dark toxicity studies, all four BODIPY conjugates showed a
moderate decrease in cell toxicity with increasing concentration, as shown in Figure S28.
BODIPY 14 showed the lowest cytotoxicity of all conjugates, with approximately 80% cell
survival at 200 μM, whereas BODIPY 13 displayed the highest cytotoxicity with
approximately 40% cell survival at 200 μM. The IC50 values, calculated from the dose
response curves, were 159 μM for 13 and above 200 μM for all other BODIPYs.
Bioconjugates 12 and 13 showed lower cell survival rates across the concentration range
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compared with 14 and 15, which may be a result of the greater accumulation of 12 and 13 in
cells because of the presence of the cationic EGFR-targeting peptide LARLLT. For
phototoxicity studies, a low light dose (1.5 J/cm2) was used and the results are shown in
Figure S29 and summarized in Table 2. The BODIPYs were found to have low
phototoxicities, with IC50 values above 100 μM, except for 12 that was found to have an
IC50 value of 94 μM. The higher observed cytotoxicity of BODIPY 12 might be a result of
its higher uptake into the HT-29 cells (Figure 5). Among all BODIPYs, conjugate 14 appears
to be the least phototoxic, which may be attributed to the observed reduced cellular uptake
for this compound. Overall, all BODIPY bioconjugates showed low cytotoxicities, making
them promising candidates as fluorescent bioimaging agents.
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2.5.4. Extracellular Localization.—The extent of extracellular localization of the
BODIPY conjugates was evaluated by fluorescence microscopy, and the results are shown in
Figures 6 and S30 of the Supporting Information. The SW 480 cells (highest EGFR
expression) and LOVO cells (lowest EGFR expression) were used in these studies. Both cell
lines were independently exposed to BODIPY conjugates 12, 13, 14, and 15 at a
concentration of 10 μM for 15 min, immediately followed by imaging. With BODIPYs 12
and 13, a significantly higher fluorescence signal was observed in the SW480 cells
compared with the LOVO cells, indicating that these compounds are actively binding to the
ECD of EGFR overexpressed in the SW480 cells. A weaker fluorescence signal was also
observed in the case of BODIPYs 14 and 15, suggesting nonspecific binding of these
compounds to the EGFR overexpressing cells. These findings are in agreement with the
results obtained in the SPR and AutoDock model studies.
2.6.

In Vivo Studies.
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BODIPYs 12 and 14 were selected for evaluation in nude mice bearing HT-29 subcutaneous
tumors on the lower right flank, and the results are shown in Figure 7. BODIPY 12
containing the EGFR-targeting peptide LARLLT was selected because of its rapid cellular
uptake, low cytotoxicity, EGFR-targeting ability, and good solubility, whereas BODIPY 14
was selected as a negative control. Nude mice were administered 100 μL of 2 mM BODIPY
12 or 14 via lateral tail vein injection, followed by fluorescence imaging at 0, 24, 48, 72, and
96 h post-injection. At time 0, the fluorescence of both compounds can clearly be seen
localized in the tail, and in the case of 12, immediate plasma circulation was observed. At 24
h, the mouse administered BODIPY 12 clearly showed tumor-selective fluorescence
indicating that this conjugate targeted the subcutaneous tumor tissue, while the signal from
14 was significantly weaker. The fluorescence signal progressively decreased with time,
indicating slow clearance of the BODIPY at 48, 72 and 96 h, with the highest signal at these
time points still within the tumor tissue. For BODIPY 14, minimal fluorescence was
observed suggesting no EGFR-targeting ability for this conjugate.

3.

CONCLUSIONS
A near-IR BODIPY bearing two isothiocyanato functional groups available for conjugation
to an EGFR-targeting peptide and/or water-solubilizing moiety was synthesized. On the
basis of previous studies, the peptide 3PEG-LARLLT was selected for EGFR-targeting, and
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glucose or biotin-en were selected for enhanced solubility of the conjugates. Five BODIPY
conjugates were prepared and characterized, three of them bearing one 3PEG-LARLLT
peptide and one or no water-solubilizing glucose or biotin group. Using AutoDock, all
conjugates were found to bind to EGFR with negative docking energies but only the peptidecontaining conjugates were able to bind to the known binding site of the LARLLT peptide,
on the ECD I of EGFR.

Author Manuscript

SPR studies indicated that BODIPY conjugates 12 and 13 bearing the EGFR-targeting
peptide exhibited specific binding to the ECD of EGFR compared with conjugates 14 and
15, both devoid of peptide, which showed only nonspecific binding to EGFR. This was
confirmed by fluorescence microscopy studies, which revealed higher extracellular
fluorescence in the high EGFR expressing cell line SW480 compared with the low EGFR
expression cell line LOVO, using conjugates 12 and 13. Competitive binding studies
revealed a dose-dependent decrease in fluorescence in cells with high and moderate EGFR
expression for conjugate 12, whereas 14 was found to have no dose-dependent response,
indicating nonspecific binding to EGFR. In vitro cytotoxicity studies showed no significant
dark nor phototoxicity in human colorectal adenocarcinoma HT-29 cells for any of the
BODIPY conjugates. BODIPYs 12 and 13 containing the EGFR-targeting peptide, displayed
similar uptake kinetics in HT-29 cells, distinct from those of conjugates 14 and 15, with 12
accumulating the most within cells in the first 12 h.

Author Manuscript

BODIPYs 12 and 14, bearing one or no EGFR-targeting peptide, respectively, were
investigated in nude mice bearing HT-29 human tumor xenografts. Conjugate 12 showed the
highest fluorescence signal at the site of the subcutaneous tumor at 24 h after iv
administration, and the signal was still visible at 48, 72, and 96 h post-injection, indicating
slow clearance from the body. On the other hand, BODIPY 14 bearing two glucose units
exhibited a much reduced fluorescence signal at the tumor site. Our results show that
BODIPY 12 exhibits high selectivity for the ECD of EGFR, low cytotoxicity, and good
aqueous solubility and is therefore a promising candidate for imaging of EGFRoverexpressing tumors.

4.
4.1.

EXPERIMENTAL SECTION
General Information.

Author Manuscript

All reagents and solvents were purchased from Sigma-Aldrich (St Louis, MO) or VWR
(Radnor, PA) and used without further purification unless otherwise stated. Dry solvents
were obtained from a Solvent Purification System Pure Solv PS-400 (Innovative
Technology, Carouge Switzerland). Melting points were determined in open capillary tubes
and are reported as is. Reactions were monitored using polyester backed 0.2 mm silica G
thin-layer chromatography (TLC) plates (Sorbent Technologies, Norcross GA), and column
chromatography was performed using 60 Å, 40–63 μM silica gel (Sorbent Technologies,
Norcross GA). All 1H NMR, 11B NMR, and 13C NMR spectra were collected using a
Bruker AVANCE III 400 MHz spectrometer or AVANCE III 500 MHz spectrometer
equipped with Prodigy TCl probe. Samples were dissolved in either deuterated chloroform
(CDCl3) or DMSO(DMSO-d6) using tetramethylsilane as an internal standard. Chemical
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shifts (δ) are reported in ppm where CDCl3 (1H: 7.27 ppm, 13C: 77.0 ppm) and DMSO-d6
(1H: 2.50 ppm) are used as references. Coupling constants (J) are reported in Hertz (Hz).
BODIPY conjugates were purified using RP-HPLC composed of a 2489 UV/vis detector, a
2545 quaternary gradient module pump and a FlexInject sample injector (Waters, Milford
MA) to a purity of ≥95% (unless otherwise noted). Separations were achieved on an XBridge BEH300 Prep C18 column (5 μm, 10 × 250 mm) equipped with an X-Bridge
BEH300 Prep guard column (300 Å, 5 μm, 10 × 10 mm) using a gradient of 50% A for 5
min, 30% A to 10% A over 13 min, 10% A to 50% A over 2 min at a flow rate of 4 mL/min
(unless otherwise noted) and analyzed with Empower 2 software. HRMS were obtained
using an Agilent 6210 ESI-TOF mass spectrometer (Agilent Technologies, Santa Clara CA)
or MALDI-TOF ultrafleXtreme mass spectrometer (Bruker, Millerica, MA).
4.2.

Synthesis of 2-Ethoxycarbonyl-4,5,6,7-tetrahydro-2H-isoindole 2.

Author Manuscript

1-nitro-1-cyclohexene 1 (1.13 g, 8.89 mmol) and ethyl isocyanoacetate (1.04 g, 9.15 mmol)
were dissolved in THF (10–15 mL), and then, DBU (1.73 g, 11.38 mmol) was added and the
solution was allowed to stir overnight at room temperature under an inert atmosphere. Next,
the reaction mixture was washed with brine and extracted with DCM. The combined organic
layers were dried over Na2SO4, and all solvents were removed under reduced pressure. The
resultant residue was purified by means of column chromatography using ethyl acetate/
hexanes 1:9 as the eluent to afford compound 2 as a pale yellow solid (1.37 g, 80%). The
spectroscopic data of this compound agree with that previously reported.36
4.3. Synthesis of 8-(3,5-Dimethoxyphenyl)-bis(3-ethoxycarbonyl-4,5,6,7-tetrahydro-2Hisoindolyl)methane 3.

Author Manuscript

2-Ethoxycarbonyl-4,5,6,7-tetrahydro-2H-isoindole 2 (0.77 g, 3.98 mmol), 3,5dimethoxybenzaldehyde (0.331 g, 1.99 mmol), p-TsOH (0.017 g, 0.996 mmol), and tertbutylammonium iodide (40 mg) were dissolved in DCM (100 mL) and allowed to stir
overnight at room temperature. The reaction mixture was then washed with saturated
NaHCO3 and extracted with DCM. The combined organic layers were dried over Na2SO4,
and the solvent was removed under reduced pressure. The resultant residue was purified by
column chromatography using ethyl acetate/hexanes 1:5 as the eluent to afford bright orange
crystals of compound 3 (0.899 g, 84%). mp 89–90 °C; 1H NMR (400 MHz, CDCl3): δ 9.39
(s, 2H), 6.33 (t, J = 2.3 Hz, 1H), 6.24 (d, J = 2.3 Hz, 4H), 5.40 (s, 1H), 4.19–4.09 (m, 4H),
3.67 (s, 6H), 2.76 (t, J = 6.3 Hz, 4H), 2.27 (t, J = 6.3 Hz, 1H), 1.73–1.64 (m, 8h), 1.24 (t, J =
7.1 Hz, 6H); HRMS (ESI-TOF) m/z: calcd for C31H39N2O6, 535.2803; found [M + H]+,
535.2811.

Author Manuscript

4.4. Synthesis of 8-(3,5-Dimethoxyphenyl)-bis(3-carboxyl-4.5.6.7-tetrahydro-2Hisoindolyl)methane 4.
Compound 3 (0.800 g, 1.50 mmol) was dissolved in THF (6 mL) and methanol (6 mL),
followed by addition of KOH solution (0.840 g, 14.9 mmol) in water (10 mL). The solution
was refluxed at 90–100 °C for 24 h and then allowed to cool to room temperature. A 1 M
solution of HCl was added to the mixture until pH of 5 was reached. The reaction mixture
was filtered and the light pink-purple precipitate was collected. For compound 4, 1H NMR
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(400 MHz, CDCl3): δ 8.75 (m, 2H), 6.37 (t, J = Hz, 1H), 6.26 (d, J = Hz, 2H), 5.34 (s, 1H),
4.21 (m, 4H), 3.72 (s, 6H), 2.79 (t, J = Hz, 4H), 2.22 (t, J = Hz, 4H), 1.69 (m, 8H), 1.30 (t, J
= Hz, 6H).
4.5. Synthesis of 8-(3,5-Dimethoxyphenyl)-bis(3-iodo-4.5.6.7-tetrahydro-2Hisoindolyl)methene 5.

Author Manuscript

Compound 4 (0.900 g, 1.88 mmol) was dissolved in methanol (40 mL) in a round-bottom
flask (RBF) followed by addition of sodium bicarbonate (1.58 g, 18.8 mmol) and distilled
water (15 mL). The RBF was then wrapped in aluminum foil to prevent light penetration
followed by addition of iodine (1.43 g, 5.64 mmol). The reaction mixture was allowed to stir
at room temperature for 72 h. The solution was then cooled in an ice bath, and stirring was
ceased. The solid was filtered, washed with cold distilled water, then dissolved in DCM, and
washed with saturated Na2S2O3. The combined organic layers were dried over Na2SO4, and
the solvent was removed under reduced pressure. The residue was purified using column
chromatography to afford a maroon solid. For compound 5, 1H NMR (400 MHz, CDCl3): δ
9.08 (s, 1H), 6.65 (d, J = 2.76, 2H), 4.31 (dd, J = 7.12 Hz, 4H), 2.83 (t, J = Hz, 4H), 2.56 (t, J
= Hz, 4H), 1.75 (m, 8H), 1.35 (t, J = Hz, 6H).
4.6.

Synthesis of 3,5-Diiodo-8-(3,5-dimethoxyphenyl)-BODIPY 6.

Author Manuscript

Compound 5 (1.20 g, 1.87 mmol) was dissolved in DCM (100 mL) and allowed to stir under
nitrogen. Triethylamine (TEA; 1.90 g,28.1 mmol) was added followed by BF3·OEt2 (3.99 g,
28.11 mmol), and the reaction was allowed to stir at room temperature for 2 h. Subsequently,
the solvent was removed under reduced pressure and the resultant residue was solubilized in
ethyl acetate and washed with 1 M HCl followed by saturated NaHCO3. The combined
organic layers were dried over Na2SO4, and the solvent was removed under reduced
pressure. The residue was then purified by column chromatography using DCM/hexanes 2:1
as the eluent to afford compound 6 as a bright pink crystalline solid (0.877 g, 68%), mp
226–227 °C; 1H NMR (400 MHz, CDCl3): δ 6.55 (t, J = 2.3 Hz, 1H), 6.39 (d, J = 2.3 Hz,
2H), 3.80 (s, 6H), 2.31 (t, J = 6.2 Hz, 4H), 1.74 (t, J = 6.2 Hz, 4H), 1.65–1.59 (m, 4 h);
HRMS (ESI-TOF) m/z: calcd for C25H24BFI2N2O2, 668.0113; found [M–F]+, 668.0098.
4.7. General procedure for Synthesis of 8-(3,5-Dimethoxyphenyl)-bis(3-p-nitrophenyl)BODIPY 7.

Author Manuscript

BODIPY 6 (0.150 g, 218.0 mmol), 4-nitrophenylboronic acid (0.182 g, 1.09 mmol), and a
catalytic amount of [1,1′-bis(diphenylphosphino)ferrocene]-palladium(II) dichloride
(Pd(dppf)Cl2) were added to an RBF under nitrogen atmosphere. THF (2–33 mL) and
toluene (2–3 mL) were added, and the solution was heated to 70–80 °C followed by addition
of 1 M K2CO3 (2.18 mL). The reaction was allowed to stir for 3 h. Subsequently, all
solvents were removed under reduced pressure, and the resultant residue was purified by
column chromatography using DCM/hexanes 3:1 as the eluent to afford compound 7 as a
deep purple crystalline solid (134.6 mg, 91%), 1H NMR (400 MHz, CDC3): δ 8.27–8.20 (m,
4H), 7.76–7.69 (m, 4H), 6.62 (t, J = 2.3 Hz, 1H), 6.53 (d, J = 2.2 Hz, 2H), 3.87 (s, 6H), 2.29
(t, J = 6.0 Hz, 4H), 1.93 (t, J = 6.1 Hz, 4H), 1.55 (d, J = 7.5 Hz, 8H), HRMS (ESI-TOF) m/z:
calcd for C37H33BF2N4O6, 677.2492; found [M]+, 677.2440.
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BODIPY 7 (0.135 g, 199.0 mmol) was solubilized in toluene (20 mL) followed by addition
of DDQ (0.407 g, 1.79 mmol). The reaction mixture was refluxed for 1.5 h, and the reaction
was followed by UV/vis. The solvent was removed under reduced pressure and washed with
saturated NaHCO3. The combined organic layers were dried over Na2SO4 and solvent was
removed under reduced pressure. The resultant residue was purified by column
chromatography using DCM/hexanes 3:1 as the eluent to afford compound 8 as a purple
crystalline solid (124.1 mg, 93%), 1H NMR (400 MHz, CDCl3): δ 8.40–8.33 (m, 4H), 8.00–
7.92 (m, 4H), 7.55–7.46 (m, 2H), 7.26–7.18 (m, 4H), 6.85 (t, J = 2.3 Hz, 2h), 6.60–6.52 (m,
2H), 3.89 (s, 6H); HRMS (ESI-TOF) m/z: calcd for C37H26BF2N4O6, 670.194; found [M +
H]+, 670.1954.
4.9.

Synthesis of 8-(3,5-dimethoxyphenyl)-bis(3-p-amino-phenyl)-BODIPY 9.

Author Manuscript

BODIPY 8 (0.0661 g, 0.0986 mmol) and palladium on carbon (0.262 g) were added to an
RBF followed by addition of ethanol (5–7 mL), THF (4–5 mL), and hydrazine (0.494 g, 9.86
mmol). The reaction mixture was refluxed for 2–3 h and followed by TLC. Next, all solvents
were removed under reduced pressure, and the residue was solubilized in DCM and passed
through a celite cake. The filtrate was collected and solvent was removed under reduced
pressure. The resultant residue was purified by column chromatography using ethyl
acetate/DCM 1:1 as the eluent to afford a dark blue solid. 1H NMR (400 MHz, CDCl3): δ
7.62–7.60 (d, J =7.3 Hz, 6H), 7.12 (m, 4H), 6.81–6.79 (d, J = 7.9 Hz, 7H), 6.52–6.50 (d, J =
7.28 Hz, 2H), 4.11–4.05 (dd, J = 14.4, 7.1 Hz, 4H), 3.85 (s, 6H); HRMS (ESI-TOF) m/z:
calcd for C37H29BF2N4O2, 590.2398; found [M – F]+, 590.2399.
4.10.

Synthesis of 8-(3,5-Dimethoxyphenyl)-bis(3-p-isothio-cyanato phenyl)-BODIPY 10.

Author Manuscript
Author Manuscript

BODIPY 9 (0.0602 g, 0.0986 mmol) was dissolved in DCM (10 mL) followed by addition
of TDP (0.0916 g, 0.349 mmol), and the reaction mixture was allowed to stir overnight at
room temperature under an inert atmosphere. The solvent was then removed under reduced
pressure, and the resultant residue was purified by column chromatography using DCM/
hexane 2:1 as the eluent to afford compound 10 as a dark blue crystalline solid (54.2 mg,
90%), mp 222–223 °C; 1H NMR (400 MHz, CDCl3): δ 7.79 (d, J = 8.5 Hz, 4H), 7.51 (m,
2H), 7.36 (d, J = 8.5 Hz, 4H), 7.16 (td, J = 6.8, 6.1, 3.4 Hz, 4H), 6.80 (dd, J = 13.6, 2.3 Hz,
3H), 6.51 (m, 2H), 3.86 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 162.10, 150.27, 136.95,
136.70, 136.67, 134.37, 132.53, 1313.82, 131.79, 131.76, 131.07, 131.05, 131.03, 130.10,
129.54, 126.78, 125.83, 125.47, 123.20, 122.12, 106.76, 102.22, 77.42, 55.91, 29.90; 11BNMR (128 MHz, CDCl3): S 1.68 (t, JBF = 30.7 Hz). HRMS (ESI-TOF) m/z: calcd for
C39H25BF2N4O2S2, 694.1589; found [M + H]+, 694.1542.
4.11.

Synthesis of Biotin-en.
Commercially obtained biotin (0.0500 g, 0.205 mmol), N-(3-dimethylaminopropyl)-N’ethylcarbo-diimide hydrochloride (0.0953 g, 0.614 mmol), and HOBt (0.830 g, 0.614 mmol)
were solubilized in DMSO (2 mL) followed by addition of TEA (0.0621 g, 0.614 mmol),
and the reaction mixture was allowed to stir at room temperature for 1–2 h. Then, N-Bocethylenediamine (0.492 g, 0.307 mmol) was added, and the reaction mixture was allowed to
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stir at room temperature for 12 h. The reaction mixture was extracted in DCM and washed in
series with saturated NH4Cl, followed by saturated NaHCO3 and finally with brine. The
combined organic layers were dried over Na2SO4, and all solvents were removed under
reduced pressure. The resultant reside was then purified by column chromatography using
DCM/methanol 9:1 as the eluent to afford the corresponding N-Boc-protected biotin as a
pearl white solid (38.0 mg, 48%), HRMS (ESI-TOF) m/z: calcd for C17H31N4O4S,
387.2061; found [M + H]+, 387.2056. This compound (0.0322 g, 0.0833 mmol) was
solubilized in 20% TFA in DCM (2 mL) and allowed to stir at room temperature for 2 h. The
reaction mixture was washed with diethyl ether to remove residual TFA, and all solvents
were removed under reduced pressure to afford compound 12 as an off-white solid. 1H NMR
(400 MHz, CDCl3): δ 7.77 (t, J = 5.6 Hz, 1H), 6.77 (t, J = 5.8 Hz, 1H), 6.41 (s, 2H), 4.30
(dd, J = 7.7, 5.1 Hz, 1H), 4.12 (ddd, J = 7.5, 4.5, 1.7, Hz, 1H), 3.07 (m, 3H), 2.95 (q, J = 6.4
Hz, 2H), 2.82 (dd, J = 12.4, 5.1 Hz, 1H), 2.57 (d, J = 12.4 Hz, 3H), 2.04 (t, J = 7.4 Hz, 2H),
1.68–1.40 (m, 5H), 1.37 (s, 10H), 1.33–1.13 (m, 5H); HRMS (ESI-TOF) m/z: calcd for
C12H23N4O2S, 287.1536; found [M + H]+, 287.1540.

Author Manuscript

4.12.

General Procedure for Conjugation of BODIPY 10.
BODIPY 10 and the biomolecule (peptide, 1-thio-β-D-glucose sodium salt or modified
biotin-en) were solubilized in anhydrous DMF or in DMSO (0.25–0.5 mL) followed by
addition of TEA (0.080 mL). The reaction mixture was covered to prevent penetration of
light and allowed to stir at room temperature for 0.5 h. The reaction was subsequently
quenched with water and then solubilized in water/MeCN 1:1 and purified using RP-HPLC.

4.13.

Synthesis of BODIPY Bioconjugate 11.

Author Manuscript

BODIPY 10 (0.004 g, 0.0058 mmol), 3PEG-LARLLT (0.016 g, 0.0144 mmol), and TEA
(0.080 mL) were used. The conjugate was purified by RP-HPLC (50% A for 5 min, 30% A
to 10% A over 13 min, 10% A to 50% A over 2 min at a flow rate of 4 mL/min) with tR =
12.405 min. The desired fractions were pooled and lyophilized to afford conjugate 11 as a
light blue solid (0.0082 mg, 90%). mp 151–152 °C; 1H NMR (500 MHz, DMSO-d6): δ
8.11–7.94 (m, 5H), 7.86 (dd, J = 11.1, 7.9 Hz, 3H), 7.75 (d, J = 8.4 Hz, 2H), 7.68 (d, J = 8.4
Hz, 2H), 7.49–7.38 (m, 3H), 7.25 (q, J = 6.7 Hz, 3H), 7.05 (d, J = 16.9 Hz, 3H), 6.90 (s, 2H),
4.27 (dp, J = 28.7, 7.3 Hz, 6H), 4.09–3.97 (m, 3h),3.82 (s, 3H), 3.68 (t, J = 5.7 Hz, 6H), 3.61
(q, J = 6.6, 5.7 Hz, 14h), 3.08 (q, J = 6.6 Hz, 2H), 2.46–2.29 (m, 4H), 1.63 (dtq, J = 26.2,
13.5,7.1 Hz, 5H), 1.54–1.47 (m, 4H), 1.47 (s, 1H), 1.43 (t, J = 7.9 Hz, 4H), 1.20 (d, J = 7.1
Hz, 4H), 1.00 (d, J = 6.3 Hz, 3H), 0.85 (ddd, J =23.3, 6.4, 3.8 Hz, 18H), 0.77 (s, 1h). HRMS
(MALDI-TOF) m/z: calcd for C79H103BF2N15O13S2+, 1581.739; found [M]+, 1581.681.

Author Manuscript

4.14.

Synthesis of BODIPY Bioconjugate 12.
Conjugate 11 (0.003 g, 0.0019 mmol) and 1-thio-β-D-glucose sodium salt (0.0021 g, 0.0095
mmol) and TEA (0.006 mL) were used. The resulting conjugate was purified by RP-HPLC
(50% A for 5 min, 30% A to 10% A over 13 min, 10% A to 50% A over 2 min at a flow rate
of 4 mL/min) with tR = 12.296 min. The desired fractions were pooled and lyophilized to
afford conjugate 12 as a light blue solid (2.80 mg, 83%). mp °C; 1H NMR (500 MHz,
DMSO-d6): δ 8.03 (dd, J = 32.4, 15.2 Hz, 5H), 7.88 (d, J = 8.8 Hz, 2H), 7.80–7.72 (m, 3H),
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7.70 (s, 2H), 7.56 (s, 1H), 7.45–7.34 (m, 4H), 7.26 (s, 2H), 7.06 (d, J = 14.9 Hz, 3H), 6.90
(dd, J = 15.8, 7.9 Hz, 3H), 6.43 (d, J = 6.8 Hz, 2H), 4.83 (s, 1H), 4.31 (dd, J = 15.5, 8.0 Hz,
3H), 4.27–4.20 (m, 3H), 4.10–4.00 (m, 4H), 3.83 (s, 3H), 3.57 (s, 6H), 3.52 (s, 8H), 3.09 (d,
J = 7.0 Hz, 2H), 2.27 (s, 1H), 1.61 (dt, J = 15.5, 8.1 Hz, 4H), 1.49 (dt, J = 28.5,13.1 Hz, 9H),
1.27–1.18 (m, 6H), 1.00 (d, J = 6.2 Hz, 3H), 0.85 (ddt, J = 21.6, 10.3, 5.7 Hz, 19H). HRMS
(MALDI-TOF) m/z: calcd for C85H115BF2N 15O18S3+, 1777.780; found [M]+, 1777.834.
4.15.

Synthesis of BODIPY Bioconjugate 13.

Author Manuscript

Conjugate 11 (0.003 g, 0.0019 mmol), modified biotin-en (0.0027 g, 0.0095 mmol), and
TEA (0.006 mL) were used. The resulting conjugate was purified by RP-HPLC (50% A for
5 min, 30% A to 10% A over 13 min, 10% A to 50% A over 2 min at a flow rate of 4 mL/
min) with tR = 12.217 min. The desired fractions were pooled and lyophilized to afford
conjugated 13 as a light blue solid (1.59 mg, 45%). mp 195–196 °C; 1H NMR (500 MHz,
DMSO-d6): δ 8.08–7.92 (m, 3H), 7.87 (t, J = 9.4 Hz, 2H), 7.75 (d, J = 8.4 Hz, 1H), 7.69 (d, J
= 8.1 Hz, 1H), 7.46 (t, J = 5.9 Hz, 1H), 7.41 (d, J = 8.3 Hz, 1H), 7.20 (s, 1H), 7.06 (d, J
=17.2 Hz, 2H), 6.89 (d, J = 17.9 Hz, 1H), 6.49 (s, 3H), 6.43 (d, J = 7.7 Hz, 1H), 4.86 (d, J =
4.9 Hz, 1H), 4.28 (dp, J = 28.4, 7.4 Hz, 4H),4.05 (ddd, J = 26.2, 9.5, 4.0 Hz, 2H), 3.83 (s,
2H), 3.69 (s, 1h), 3.64–3.56 (m, 4H), 3.54–3.46 (m, 4H), 3.08 (t, J = 6.7 Hz, 2H), 2.37–2.32
(m, 1h), 1.61 (dq, J = 12.5, 6.4 Hz, 3H), 1.48 (ddq, J =19.7, 13.2, 8.0, 6.4 Hz, 7 h), 1.27–
1.15 (m, 4 h), 1.00 (d, J = 6.2 Hz, 2H), 0.86 (dt, J = 24.0, 5.5 Hz, 13H). HRMS (MALDITOF) m/z: calcd for C91H125BF2N19O15S3+, 1867.886; found [M]+, 1867.919.
4.16.

Synthesis of BODIPY Bioconjugate 14.

Author Manuscript

BODIPY 10 (0.003 g, 0.0043 mmol), 1-thio-β-D-glucose sodium salt (0.0024 g, 0.011
mmol), and TEA (0.006 mL) were used. The resulting conjugate was purified by RP-HPLC
(50% A for 5 min, 30% A to 10% A over 13 min, 10% A to 50% A over 2 min at a flow rate
of 4 mL/min) with tR = 22.505 min. The desired fractions were pooled and lyophilized to
afford conjugate 14 as a light blue solid (2.02 mg, 43%). mp 262–263 °C; 1H NMR (500
MHz, DMSO-d6): δ 7.79 (d, J = 8.0 Hz, 4H), 7.62 (d, J = 8.0 Hz, 4H), 7.53 (d, J = 7.8 Hz,
2H), 7.28 (p, J = 7.0 Hz, 4H), 6.92 (s, 3H), 6.49 (s, 5H), 6.45 (d, J = 8.1 Hz, 2H),3.83 (s,
7H), 3.29 (s, 8H), 2.09 (s, 10H). HRMS (MALDI-TOF) m/z: calcd for
C51H49BF2N4O12S4+, 1085.232; found [M]+, 1085.410.
4.17.

Synthesis of BODIPY Bioconjugate 15.

Author Manuscript

BODIPY 10 (0.003 g, 0.0019 mmol), modified biotin-en, and TEA (0.006 mL) were used.
The resulting conjugate was purified by RP-HPLC (50% A for 5 min, 30% A to 10% A over
13 min, 10% A to 50% A over 2 min at a flow rate of 4 mL/min) with tR = 11.980 min. The
desired fractions were pooled and lyophilized to afford compound 15 as a light blue solid
(0.602 mg, 11%). mp 210–211 °C; 1H NMR (500 MHz, DMSO-d6): δ 9.92 (s, 1H), 8.08 (s,
1H), 7.94 (s, 1H), 7.70 (t, 8.7 Hz, 4H), 7.57 (s, 2H), 7.25 (s, 4H), 6.91 (s, 2H), 6.62–6.17 (m,
6H), 4.28 (s, 1H), 4.11 (s, 1H), 3.83 (s, 4H), 3.29 (s, 24H), 2.09 (s, 18H). HRMS (MALDITOF) m/z: calcd for C63H69BF2N12O6S4+, 1265.444; found [M]+, 1265.293.
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X-ray data were collected at low temperature with Mo Kα radiation on Bruker Kappa ApexII DUO diffractometer. Crystal data: 10 C39H25BF2N4O2S2 Mr = 694.56, triclinic, a =
8.9803(4) Å, b = 12.7742(6) Å, c = 14.8284(8) Å, α = 100.414(2)°, β = 98.207(2)°, γ; =
93.875(2)°, T = 180 K, space group P1, Z = 2, 20 404 reflections measured, 5945
independent (Rint = 0.029), θmax = 69.3°, R = 0.036.
4.19.

Steady-State Absorption and Fluorescence Spectroscopy.

Author Manuscript

Spectroscopic properties of BODIPY conjugates were determined in DMSO. All
experiments were carried out within 3 h of solution preparation at room temperature (23–
25 °C) using a 10 mm path length spectrophotometric cell. All absorption spectra were
measured using a Varian Cary 50 Bio UV/vis spectrophotometer (Agilent Technologies,
Santa Clara CA). Emission spectra were recorded on a PerkinElmer LS 55 fluorescence
spectrometer (PerkinElmer, Waltham MA). The fluorescence quantum yields (ФF) were
determined using a secondary standard method using methylene blue (ФF = 0.035) as the
reference.41
4.20.

Surface Plasmon Resonance.
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Surface plasmon resonance studies were conducted using immobilized EGFR on a CM5
sensor chip via standard amine coupling with a Biacore X100 (GE Healthcare Life Sciences,
Marlborough MA). Running buffer used was 4% DMSO in 1× HBS-EP + [0.01 M N-(2hydroxyethyl)-piperazine-N′-ethanesulfonic acid, 0.15 M NaCl, 3 mM ethylenediaminetetraacetic acid (EDTA), 0.005% Tween, pH 75] (GE Healthcare Biosciences), at
a flow rate of 5 μL/min. All solutions were prepared in running buffer and filtered using a
0.45 μm filter. All SPR sensorgrams measure association and dissociation rates of analytes at
concentrations of 0–300 μM performed at 25 °C.
4.21.

Competitive Binding Studies.

Author Manuscript

Cells SW-480, HT-29, DLD-1, and LoVo were grown to confluency. About 10 000 cells of
each cell line were coated in a 96 well tissue culture black plate and incubated overnight at
37 °C with 5% CO2. After 24 h, the medium was removed, and different concentrations
(0.25–100 μM) of cyclo(K(N3)larllt)32 with a constant concentration (50 μM) of conjugate
12 or 14 was added to the wells in triplicate. Phosphate-buffered saline (PBS) was used for
dilution of compounds. The plate was then covered in aluminum foil and incubated at 37 °C
with 5% CO2. After 45 min, each well was washed twice with 100 μL of PBS, and
fluorescence was determined with a microplate reader using an excitation wavelength of 647
nm and an emission wavelength of 683 nm. Autofluorescence values were subtracted from
each well. A plot of concentrations versus relative fluorescence was plotted. Results are
expressed as ±S.D.
4.22.

Molecular Modeling and Docking.
The structure of compounds and conjugates were generated using Insight II (BIOVIA, San
Diego CA) molecular modeling software on a Linux workstation. Generated 3D structures
were subjected to molecular dynamics (MD) at 900 K and each structure was subjected to
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simulated annealing procedure by decreasing the temperature from 900 to 300 K in steps of
100 K. At each step, 10 ps MD simulations were carried out. Structures obtained after 300 K
dynamics were energy minimized. The resulting structure was used for docking studies.
Docking studies were conducted using AutoDock39 with AutoDock tools. Before docking
calculations were performed, the boron atom was replaced with a carbon atom in the
conjugate, as boron parameters are not validated in the AutoDock 4. The EGFR protein
structure was downloaded from protein data bank (PDB ID 1nql).40 Docking calculations
were performed as described before in our earlier reports.21 Briefly, a grid box (AutoDock
tools 4) was created around domain I of ECD of EGFR and compounds 10, 11–15 were
docked to EGFR using Lamarckian genetic algorithm, and 10 million energy evaluations
were performed. For conjugate 11 docking, a grid box was created between the domain I and
II of EGFR and docking calculations were performed using 10 million energy evaluations.
Final docked structures were represented using PyMol software (Schrödinger LLC, Portland
OR).
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4.23.

Cell Studies.
All cell culture media and reagents were purchased from Invitrogen unless otherwise stated.
Human colorectal adenocarcinoma cell lines HT-29 (ATCC HTB-38), SW480 (ATCC
CCL-227) and LoVo (ATCC CCL-229) were purchased from ATCC and maintained at 37 °C
under 5% CO2 in McCoys 5A medium, Leibovitz’s L-15 medium and Ham’s F-12K
(Kaighn’s) medium/Dulbecco’s modified Eagle medium, respectively, all augmented with
10% fetal bovine serum (FBS) and 1% penicillin–streptomycin (P/S). Working stock
solutions of BODIPY conjugates were prepared at 32 mM in 4% DMSO and 1%
Cremophor-EL in Dulbecco’s phosphate-buffered saline (1× PBS).
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4.24.

Time-Dependent Cellular Uptake.
HT-29 cells were plated in a Corning Costar 96-well plate and were allowed to grow 48 h to
reach approximately 7500 cells per well. Working stock solutions of BODIPY conjugates
were diluted with McCoys 5A medium augmented with 10% FBS and 1% P/S to 20 μM.
Cells were exposed to BODIPY conjugates at a final concentration of 10 μM at 0, 1, 2, 4, 8,
and 24 h time intervals. At the end of the incubation period, the loading medium was
removed, and cells were washed with 200 μL of 1× PBS and then solubilized with 100 μL of
0.25% Triton X-100 (Calbiochem, San Diego CA) in 1× PBS. The CyQUANT Cell
Proliferation Assay Kit (Invitrogen, Carlsbad CA) was utilized for cell quantification.
BODIPY concentrations were determined by fluorescence intensity at 640/680 nm
(excitation/emission) using a FLUOstar OPTIMA microplate reader (BMG Labtech, Cary
NC). The cellular uptake is expressed in nM of compound per cell.
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4.25.

Dark Cytotoxicity.
HT-29 cells were plated as previously described above and allowed to incubate for 48 h.
Subsequently, cells were exposed to BODIPY conjugate at increasing concentrations (6.25,
12.5, 25, 50, 100, and 200 μM) and then incubated overnight (20–24 h) at 37 °C under 5%
CO2. Immediately following incubation, the loading medium was removed and cells were
washed in triplicate with media to remove any residual BODIPY compound. Cells were then
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fed McCoys 5A medium containing 20% CTB (Promega, Madison WI) and incubated for 4
h at 37 °C under 5% CO2. Cell viability was determined by fluorescence intensity at
570/615 nm using a FLUOstar OPTIMA microplate reader. Cell dark toxicity is expressed
as a percentage of viable cells.
4.26.

Phototoxicity.

Author Manuscript

HT-29 cells were plated as previously described above and allowed to incubate for 48 h.
Subsequently, cells were exposed to BODIPY conjugate at increasing concentrations (3.125,
6.25, 12.5, 25, 50, and 100 ^M) and then incubated overnight (20–24 h) at 37 °C under 5%
CO2. Immediately after incubation, the loading medium was removed and cells were washed
in triplicate with media to remove any residual BODIPY compound. Cells were then fed
McCoys 5A medium and exposed to light using a 600W Quartz Tungsten Halogen lamp
(Newport Corporation, Irvine CA) to generate a light dose of 1.5 J/cm2. Cells were exposed
for 20 min while the plate rested on an EchoTherm IC50 chilling/heating plate (Torrey Pines
Scientific, Carlsbad CA) set to 5 °C to maintain ambient temperature. Following light
exposure, cells were incubated for 24 h, after which the media were removed and replaced
with 20% CTB in McCoys 5A medium and subsequently incubated for 4 h. Cell viability
was determined by fluorescence intensity at 570/615 nm using a FLUOstar OPTIMA
microplate reader. Cell phototoxicity is expressed as a percentage of viable cells.
4.27.

Microscopy.
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HT-29 cells were plated in a 35 mm tissue culture dish (CELLTREAT, Pepperell MA) and
were allowed to grow overnight. Cells were exposed to BODIPY conjugates at a final
concentration of 10 μM then immediately incubated at 37 °C for 15 min. Following the
incubation period, the loading media were removed and the cells were washed with 1 × PBS
in triplicate. Cells were imaged submerged/immersed in 1× PBS, 0.25% Triton X-100.
Images were captured/acquired using a Leica DM RXA2 (DM6Bs) motorized upright
confocal laser scanning microscope (Leica; Wetzlar, Germany) equipped with a water
immersion objective and fitted with standard Texas Red, FITC, DAPI, GFP, YFP, TRITC,
and Cy5LP filter cubes (Chroma Technology Corporation, Bellows Falls VA).
4.28.

Animal Studies.
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For animal studies, athymic nu/nu mice (Charles River Laboratories, Wilmington MA) were
purchased at 6 weeks of age and quarantined for 1 week. Subsequently, the human colorectal
adenocarcinoma HT-29 cell line (ATCC; Manassas, VA) was implanted subcutaneously in
the lower right flank. Initially, HT-29 cells were cultured in a McCoy’s 5A medium
containing 10% FBS (Atlanta Biologicals; Flowery Branch, GA) to approximately 75%
confluence, treated with 0.25% (w/v) trypsin—0.53 mM EDTA solution, concentrated via
centrifugation, and resuspended in Dulbecco’s PBS before injection. The cells were
incubated at 37 °C and 5% CO2 under humidified conditions. Each of the mice was injected
with 5 × 106 cells in 0.1 mL PBS. Tumors were allowed to develop until palpable
(approximately 2 weeks), after which mice were subjected to lateral tail vein injection of
BODIPY conjugates at 2 mM in 10% DMSO and 5% Cremophor EL in Dulbecco’s PBS.
After injection, the mice were observed for acute adverse responses and then anesthetized
using 3% isoflurane for imaging. Fluorescence imaging was performed at 10 min after
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injection and at 1, 2, 3, 4, and 5 days using a Spectral AMI optical imaging system (Spectral
Instruments Imaging; Tucson, AZ) set at excitation 640 nm and emission 690 nm. All
experimental protocols involving live animals were reviewed and approved by the
Institutional Animal Care and Use Committee (IACUC) of LSU.
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3PEG

tri(ethylene) glycol

Boc

tert-butyloxycarbonyl

BODIPY

4,4-difluoro-4-bora-3a,4a-diaza-s-indacene

CrEL

Cremo-phor EL

CTB

CellTiter-Blue

DBU

1,8-diazabicyclo[5.4.0]-undec-7-ene

DCM

dichloromethane

DDQ

2,3-dichloro-5,6-dicyano-1,4-benzoquinone

DIPEA

diisopropylethylamine

DMF

dimethylformamide

ECD

extracellular domain

EGFR

epidermal growth factor receptor

en

ethylenediamine

ESI-TOF

electrospray ionization-time of flight

EtOAc

ethyl acetate

EtOH

ethanol

Fmoc

fluorenylmethyloxycarbonyl
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HBTU

O-benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluorophosphate

HOAt

1-hydroxy-7-azabenzotriazole

HOBt

1-hydroxybenzotriazole

HRMS

high resolution mass spectrometry

HSQC

heteronuclear single quantum correlation

IR

infrared

iv

intravenous

MALDI-TOF MS

matrix assisted laser desorption ionization-time of flight
mass spectrometry

MeOH

methanol

MQ

Milli-Q

NIR

near infrared

NMR

nuclear magnetic resonance

P (dppf)Cl2

[1,1′-bis-(diphenylphosphino)ferrocene]dichloropalladium
(II)

rt

room temperature

RTK

receptor tyrosine kinase

RP-HPLC

reversed phase-high performance liquid chromatography

SPPS

solid-phase peptide synthesis

TEA

triethyl-amine

TDP

1,1′-thiocarbonyldi-2(1H)-pyridone

TFA

tri-fluoroacetic acid

TGF-α

transforming growth factor-α

THF

tetrahydrofuran

TIPS

triisopropylsilane

TKI

tyrosine kinase inhibitor

TLC

thin layer chromatography

TsOH

p-toluenesulfonic acid

UV–vis

ultraviolet–visible
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Figure 1.

X-ray crystal structure of BODIPY 10 with 50% ellipsoids.
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Figure 2.
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Binding of BODIPYs to EGFR by SPR analysis. BODIPYs (A) 12 and (B) 13 at 250
(orange), 200 (blue), 100 (dark gray), 50 μM (yellow), 25 μM (dark blue), 10 μM (green), 1
μM (light blue), 0.5 μM (pink), 0.25 μM (light gray), and 0 μM (peach) concentrations.
EGFR was immobilized and the BODIPYs were used as the analyte to study kinetics of
association and dissociation.
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Figure 3.
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Model of interaction of BODIPYs with EGFR protein using AutoDock. Docking of
BODIPYs 12 (A) and 14 (B) were performed with similar parameters and the lowest energy
docked structures are represented. The ECD I of EGFR (PDB ID 1NQL)40 is shown as
surface representation and compounds are shown as sticks (magenta). Possible hydrophobic
interactions are shown in blue and polar interactions are shown in red. Amino acids of
EGFR are represented by a three letter code, and those on peptide are indicated by a single
letter code. Note the possible binding of 14 at a different site, shown in a rectangle buried
deep inside EGFR, compared with that of 12 o the LARLLT peptide binding site.
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Figure 4.

Competitive binding of BODIPY 12 (50 μM) with cyclo(K(N3)larllt). Binding of 12 to (A)
SW480 cells (129% EGFR expression), (B)HT-29 (78% EGFR expression), (C) DLD-1
(37% EGFR expression), (D) LOVO (6% EGFR expression). (Fluorescence without
cyclo(K(N3)larllt) (0 μM) is considered 100% relative fluorescence where all other
fluorescence values reported for increasing concentrations of cyclo(K(N3)larllt) are with
respect to 100% fluorescence).
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Figure 5.

Time-dependent cellular uptake of compounds 12 (blue), 13 (green), 14 (pink), and 15
(purple) by HT-29 cells over 24 h.
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Figure 6.
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Extracellular membrane localization of BODIPYs in SW480 cells (left panels) and LOVO
cells (right panels) after 15 min incubation period. (a) Phase contrast for SW480 and (b)
LOVO cells, fluorescence of (c,d) 12 and (e,f) 13. Scale bar: 5 μm.
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Figure 7.
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Fluorescent images (Ex./Em. 640/690 nm) of nude mice bearing sc tumor implants of HT-29
colorectal adenocarcinoma cells following intravenous (iv) administration of BODIPY
conjugates. Negative control (left) and conjugates 12 (center), and 14 (right) at 0 (A), 24 (B),
48 (C), 72 (D), and 96 h (E).
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Scheme 1. Synthesis of Bis(N C S)-BO IPY 10a
aReaction conditions: (a) ethyl isocyanoacetate, DBU, THF, rt overnight (80%); (b) 3,5-
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dimethoxybenzaldehyde, p-toluenesulfonic acid, n-tert-butylammonium iodide,
dichloromethane (DCM), rt overnight (84%); (c) 1 M KOH, THF, methanol, reflux for 24 h,
then 1 M HCl; (d) I2, NaHCO3, H2O/methanol, rt for 72 h; (e) BF3·OEt2, Et3N, DCM, rt for
2 h (68%); (f) 4-nitrophenylboronic acid, Pd(dppf)Cl2, K2CO3, THF/toluene, reflux for 3 h
(73–99%); (g) DDQ toluene, reflux for 1.5 h (54–93%); (h) hydrazine, Pd/C, ethanol/THF,
reflux for 3 h; (i) TDP, DCM, rt overnight (90%).
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Scheme 2. Synthesis of BODIPY Conjugates 11, 12, 13, 14, and 15a
aReaction conditions: (a) 3PEG-LARLLT, Et N, DMF, rt for 30 min (90%); (b) R1-H or R23

H, Et3N, DMSO, rt for 30 min (11–83%).
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Spectroscopic Properties of BODIPY Conjugates 11–15 in DMSO and Their Calculated PSA
λmax (nm)
BODIPY

Abs.

Em.

Stokes’ shift (nm)

ε (M−1 cm−1)

PSA (Å2)

ΦF

11

656

69S

39

13 700

393.27

0.37

12

657

696

39

44 200

483.09

0.47

13

650

689

39

72 600

475.20

0.44

14

656

694

38

35 750

231.96

0.47

15

655

695

40

46 700

216.18

0.47
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Table 2.
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IC50 Values for Bioconjugates 12, 13, 14, and 15 Using Cell Titer Blue Assay in Human HT-29 Cells
compound

dark toxicity (IC50, μM)

phototoxicity (IC50, μM)

12

>200

94

13

159

>100

14

>200

>100

15

>200

>100
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